A phase II study of AZD2171 [cediranib] in subjects with recurrent small volume ovarian, primary peritoneal serous or fallopian tube cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Feb 2012
At a glance
- Drugs Cediranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Feb 2012 Planned End Date changed from 1 May 2006 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.